This study will compare how well EXC 001 works versus placebo in reducing the appearance of scars in subjects undergoing elective abdominoplasty. The study will also evaluate the safety of EXC 001 in healthy adult subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
41
Scripps medical
La Jolla, California, United States
Northwestern University,Division of Plastic Surgery
Chicago, Illinois, United States
Barnes Jewish West County Hospital
St Louis, Missouri, United States
Body Aesthetic Plastic Surgery
St Louis, Missouri, United States
Expert Panel Scar Assessment Score at Week 12: Part B
Scar assessment by an expert panel was done on blinded photographs using 100 millimeter (mm) visual analog scale (VAS) where a score of 0 = best possible scar and a score of 100 = worst possible scar. A pair of photographs for each participant were presented and evaluated 3 times by an expert panel.
Time frame: Week 12
Expert Panel Scar Assessment Score at Week 24: Part B
Scar assessment by an expert panel was done on blinded photographs using 100 mm VAS where a score of 0 = best possible scar and a score of 100 = worst possible scar. A pair of photographs for each participant was presented and evaluated 3 times by an expert panel.
Time frame: Week 24
Physician Observer Scar Assessment Score at Week 12 and 24: Part B
Physician assessment of scar was done using a valid published 10-point rating scale. Physician rated vascularity, pigmentation, thickness, relief, pliability, surface area and overall opinion for a scar on a score of 1 = normal skin to 10 = worst scar imaginable. Composite score was the sum of all the scores except the overall opinion score and range from 6 (best score) to 60 (worst score).
Time frame: Week 12 and 24
Participants Observer Scar Assessment Score at Week 12 and 24: Part B
Participants rated pain, itching, color, stiffness, thickness, irregularity, and overall opinion of scar on 10-point scale. For pain and itching associated with scar: range = 1 (no, not at all) to 10 (yes, worst imaginable) and for other parameters associated with scar compared to normal skin: range = 1 (no, same as normal skin) to 10 (yes, very different). Composite score = sum of all scores except overall opinion, range 6 (best) to 60 (worst). Scar appearance composite score = sum of all scores except overall opinion, pain and itching, range 4 (best) to 40 (worst).
Time frame: Week 12 and 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Jewell Plastic Surgery Center
Eugene, Oregon, United States
Connall Consmetic Surgery
Tualatin, Oregon, United States
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included SAEs and all non-SAEs that occurred during the study.
Time frame: Day 1 of Part A up to Week 24 of Part B
Number of Participants With Abnormal Physical Examinations Findings: Part A and Part B
Physical examination included the assessment of skin; head, ears, eyes, nose, and throat; respiratory; cardiovascular; abdomen; musculoskeletal; neurological; gastrointestinal; genitourinary; endocrine and lymph nodes. Abnormal physical examinations findings was based on investigator's discretion.
Time frame: Day 1 of Part A up to Week 12 of Part B
Number of Participants With Clinically Significant Findings in Electrocardiogram (ECG): Part A and Part B
Number of participants with clinically significant abnormality in ECG were reported. Clinical significance was based on investigator's discretion.
Time frame: Day 1 of Part A up to Week 12 of Part B
Number of Participants With Clinically Significant Findings in Laboratory Examinations: Part A and Part B
Laboratory analysis included hematology, biochemistry and urinalysis. Hematology range: basophils (bas) 0-0.2, eosinophils (eos) 0-0.4, leukocytes (leu) 4-10.5, lymphocytes (lym) 0.7-4.5, neutrophils (neu) 1.8-7.8, platelet 140-415, monocytes (mon) 0.1-1 in 10\^9 per liter; bas/leu 0-3, eos/leu 0-7, lym/leu 14-46, mon/leu 4-13, neu/leu and neu/leu 40-74 in percentage, erythrocytes 3.8-5.1 10\^12/L, hematocrit 0.34-0.44 L/L, hemoglobin 115-150 gram per liter (g/L). Biochemistry range: creatine kinase 24-173, alkaline phosphatase 25-150, alanine aminotransferase (AT) and aspartate AT 0-40 in International units per liter; creatinine 50-88, urate 89-399, bilirubin 2-21 in micromole per liter, glucose 3.6-5.5, potassium 3.5-5.5, sodium 135-148, blood urea nitrogen 1.8-9.3 in millimole/L, albumin 35-55 g/L. Urinalysis parameters: pH (5-7.5), specific gravity (1.005-1.03). Participants with clinically significant findings were reported.
Time frame: Day 1 of Part A up to Week 12 of Part B
Number of Participants With Clinically Significant Findings in Vital Signs and Weight: Part A and Part B
Following vital sign parameters were assessed: diastolic blood pressure, systolic blood pressure, respiration rate, pulse rate, and temperature. Number of participants with clinically significant change in any vital sign parameter and weight compared to baseline were reported. Clinical significance was based on investigator's discretion.
Time frame: Day 1 of Part A up to Week 12 of Part B
Number of Participants With Positive Skin Sensitivity Reaction: Part A and Part B
Participants were instructed to inform the investigator in case of any itching, redness, pain or any other symptom that appears to be a rash at the injection sites. Erythematous, raised (indurated) and edematous reactions were considered as positive skin sensitivity reactions.
Time frame: Day 21 of Part A up to Day 14 of Part B